D-1439-2014 Class III Terminated

Recalled by Teva Pharmaceuticals USA — North Wales, PA

FDA drug recall D-1439-2014 was initiated by Teva Pharmaceuticals USA on Jun 17, 2014 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: out of specification impurity test results. The recall status is terminated (terminated Mar 9, 2015). Affected quantity: 5265 blister packs.

Recall details

Product Type
Drugs
Report Date
Jul 23, 2014
Initiation Date
Jun 17, 2014
Termination Date
Mar 9, 2015
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
5265 blister packs

Product description

Velivet (desogestrel and ethinyl estradiol tablets - triphasic regimen), 0.1 mg/0.025 mg; 0.125 mg/0.025 mg; 0.15 mg/0.025 mg, 3 Dispensers x 28 Tablets, Barr Laboratories, Inc., Pomona, NY NDC 0555-9051-67

Reason for recall

Failed Impurities/Degradation Specifications: out of specification impurity test results.

Distribution pattern

Nationwide

Code information

Lot 33805449A, Exp. 12/14

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1439-2014
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1439-2014. Report a data issue: hello@regdatalab.com.